,Drug,Gene1,Phenotype1,Gene2,Phenotype2,Recommendation
0,tacrolimus,CYP3A5,Normal Metabolizer,None,None,Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.
1,tacrolimus,CYP3A5,Intermediate Metabolizer,None,None,Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.
2,tacrolimus,CYP3A5,Possible Intermediate Metabolizer,None,None,None
3,tacrolimus,CYP3A5,Poor Metabolizer,None,None,Initiate therapy with standard recommended dose. Use therapeutic drug monitoring to guide dose adjustments.
4,tacrolimus,CYP3A5,Indeterminate,None,None,None
5,efavirenz,CYP2B6,Ultrarapid Metabolizer,None,None,Initiate efavirenz with standard dosing (600 mg/day).
6,efavirenz,CYP2B6,Rapid Metabolizer,None,None,Initiate efavirenz with standard dosing (600 mg/day).
7,efavirenz,CYP2B6,Normal Metabolizer,None,None,Initiate efavirenz with standard dosing (600 mg/day).
8,efavirenz,CYP2B6,Intermediate Metabolizer,None,None,Consider initiating efavirenz with decreased dose of 400 mg/day.
9,efavirenz,CYP2B6,Poor Metabolizer,None,None,Consider initiating efavirenz with decreased dose of 400 or 200 mg/day.
10,efavirenz,CYP2B6,Indeterminate,None,None,None
11,meloxicam,CYP2C9,Normal Metabolizer,None,None,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."
12,meloxicam,CYP2C9,Intermediate Metabolizer,None,None,"Initiate therapy with recommended starting dose. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."
13,meloxicam,CYP2C9,Poor Metabolizer,None,None,"Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE)."
14,meloxicam,CYP2C9,Indeterminate,None,None,None
15,piroxicam,CYP2C9,Normal Metabolizer,None,None,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."
16,piroxicam,CYP2C9,Intermediate Metabolizer,None,None,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."
17,piroxicam,CYP2C9,Poor Metabolizer,None,None,"Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE)."
18,piroxicam,CYP2C9,Indeterminate,None,None,None
19,tenoxicam,CYP2C9,Normal Metabolizer,None,None,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."
20,tenoxicam,CYP2C9,Intermediate Metabolizer,None,None,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."
21,tenoxicam,CYP2C9,Poor Metabolizer,None,None,"Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE)."
22,tenoxicam,CYP2C9,Indeterminate,None,None,None
23,celecoxib,CYP2C9,Normal Metabolizer,None,None,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."
24,celecoxib,CYP2C9,Intermediate Metabolizer,None,None,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."
25,celecoxib,CYP2C9,Poor Metabolizer,None,None,"Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo."
26,celecoxib,CYP2C9,Indeterminate,None,None,None
27,flurbiprofen,CYP2C9,Normal Metabolizer,None,None,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."
28,flurbiprofen,CYP2C9,Intermediate Metabolizer,None,None,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."
29,flurbiprofen,CYP2C9,Poor Metabolizer,None,None,"Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo."
30,flurbiprofen,CYP2C9,Indeterminate,None,None,None
31,ibuprofen,CYP2C9,Normal Metabolizer,None,None,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."
32,ibuprofen,CYP2C9,Intermediate Metabolizer,None,None,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."
33,ibuprofen,CYP2C9,Poor Metabolizer,None,None,"Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo."
34,ibuprofen,CYP2C9,Indeterminate,None,None,None
35,lornoxicam,CYP2C9,Normal Metabolizer,None,None,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."
36,lornoxicam,CYP2C9,Intermediate Metabolizer,None,None,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."
37,lornoxicam,CYP2C9,Poor Metabolizer,None,None,"Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo."
38,lornoxicam,CYP2C9,Indeterminate,None,None,None
39,fluvastatin,CYP2C9,Normal Metabolizer,SLCO1B1,Increased Function,Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines.
40,fluvastatin,CYP2C9,Normal Metabolizer,SLCO1B1,Normal Function,Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines.
41,fluvastatin,CYP2C9,Normal Metabolizer,SLCO1B1,Possible Decreased Function,Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day.
42,fluvastatin,CYP2C9,Normal Metabolizer,SLCO1B1,Decreased Function,Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day.
43,fluvastatin,CYP2C9,Normal Metabolizer,SLCO1B1,Poor Function,"Prescribe <=40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (>40mg) or an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses >40mg per day."
44,fluvastatin,CYP2C9,Normal Metabolizer,SLCO1B1,Indeterminate,"Based on CYP2C9 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. SLCO1B1 phenotype could not be assigned based on genotyping."
45,fluvastatin,CYP2C9,Normal Metabolizer,SLCO1B1,None,"Based on CYP2C9 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. SLCO1B1 genotype result is not available."
46,fluvastatin,CYP2C9,Intermediate Metabolizer,SLCO1B1,Increased Function,"Prescribe <=40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391)."
47,fluvastatin,CYP2C9,Intermediate Metabolizer,SLCO1B1,Normal Function,"Prescribe <=40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391)."
48,fluvastatin,CYP2C9,Intermediate Metabolizer,SLCO1B1,Possible Decreased Function,"Prescribe <=20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391)."
49,fluvastatin,CYP2C9,Intermediate Metabolizer,SLCO1B1,Decreased Function,"Prescribe <=20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391)."
50,fluvastatin,CYP2C9,Intermediate Metabolizer,SLCO1B1,Poor Function,Prescribe an alternative statin depending on the desired potency. (see Table 2 and Figure 1 of PMID: 35152405 for recommendations for alternative statins).
51,fluvastatin,CYP2C9,Intermediate Metabolizer,SLCO1B1,Indeterminate,"Based on CYP2C9 status, prescribe <=40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping."
52,fluvastatin,CYP2C9,Intermediate Metabolizer,SLCO1B1,None,"Based on CYP2C9 status, prescribe <=40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available."
53,fluvastatin,CYP2C9,Poor Metabolizer,SLCO1B1,Increased Function,"Prescribe <=20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391)."
54,fluvastatin,CYP2C9,Poor Metabolizer,SLCO1B1,Normal Function,"Prescribe <=20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391)."
55,fluvastatin,CYP2C9,Poor Metabolizer,SLCO1B1,Possible Decreased Function,Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).
56,fluvastatin,CYP2C9,Poor Metabolizer,SLCO1B1,Decreased Function,Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).
57,fluvastatin,CYP2C9,Poor Metabolizer,SLCO1B1,Poor Function,Prescribe an alternative statin depending on the desired potency (see Table 2 and Figure 1 of PMID: 35152405 for recommendations for alternative statins).
58,fluvastatin,CYP2C9,Poor Metabolizer,SLCO1B1,Indeterminate,"Based on CYP2C9 status, prescribe <=20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping."
59,fluvastatin,CYP2C9,Poor Metabolizer,SLCO1B1,None,"Based on CYP2C9 status, prescribe <=20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available."
60,fluvastatin,CYP2C9,Indeterminate,SLCO1B1,Increased Function,"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. CYP2C9 phenotype could not be assigned based on genotyping."
61,fluvastatin,CYP2C9,Indeterminate,SLCO1B1,Normal Function,"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. CYP2C9 phenotype could not be assigned based on genotyping."
62,fluvastatin,CYP2C9,Indeterminate,SLCO1B1,Possible Decreased Function,"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 phenotype could not be assigned based on genotyping."
63,fluvastatin,CYP2C9,Indeterminate,SLCO1B1,Decreased Function,"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 phenotype could not be assigned based on genotyping."
64,fluvastatin,CYP2C9,Indeterminate,SLCO1B1,Poor Function,"Based on SLCO1B1 status, prescribe <=40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (>40mg) or an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy)(PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses >40mg per day. CYP2C9 phenotype could not be assigned based on genotyping."
65,fluvastatin,CYP2C9,Indeterminate,SLCO1B1,Indeterminate,None
66,fluvastatin,CYP2C9,Indeterminate,SLCO1B1,None,None
67,fluvastatin,CYP2C9,None,SLCO1B1,Increased Function,"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. CYP2C9 genotype result is not available."
68,fluvastatin,CYP2C9,None,SLCO1B1,Normal Function,"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. CYP2C9 genotype result is not available."
69,fluvastatin,CYP2C9,None,SLCO1B1,Possible Decreased Function,"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 genotype result is not available."
70,fluvastatin,CYP2C9,None,SLCO1B1,Decreased Function,"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 genotype result is not available."
71,fluvastatin,CYP2C9,None,SLCO1B1,Poor Function,"Based on SLCO1B1 status, prescribe <=40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (>40mg) or an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses >40mg per day. CYP2C9 genotype result is not available."
72,fluvastatin,CYP2C9,None,SLCO1B1,Indeterminate,None
73,fluvastatin,CYP2C9,None,SLCO1B1,None,None
74,rosuvastatin,ABCG2,Normal Function,SLCO1B1,Increased Function,Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.
75,rosuvastatin,ABCG2,Normal Function,SLCO1B1,Normal Function,Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.
76,rosuvastatin,ABCG2,Normal Function,SLCO1B1,Possible Decreased Function,Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.
77,rosuvastatin,ABCG2,Normal Function,SLCO1B1,Decreased Function,Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.
78,rosuvastatin,ABCG2,Normal Function,SLCO1B1,Poor Function,"Prescribe <=20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose > 20mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391)."
79,rosuvastatin,ABCG2,Normal Function,SLCO1B1,Indeterminate,"Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. SLCO1B1 phenotype could not be assigned based on genotyping."
80,rosuvastatin,ABCG2,Normal Function,SLCO1B1,None,"Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. SLCO1B1 genotype result is not available."
81,rosuvastatin,ABCG2,Decreased Function,SLCO1B1,Increased Function,Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.
82,rosuvastatin,ABCG2,Decreased Function,SLCO1B1,Normal Function,Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.
83,rosuvastatin,ABCG2,Decreased Function,SLCO1B1,Possible Decreased Function,Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.
84,rosuvastatin,ABCG2,Decreased Function,SLCO1B1,Decreased Function,Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.
85,rosuvastatin,ABCG2,Decreased Function,SLCO1B1,Poor Function,"Prescribe <=20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391)."
86,rosuvastatin,ABCG2,Decreased Function,SLCO1B1,Indeterminate,"Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific guidelines and specific population guidelines. SLCO1B1 phenotype could not be assigned based on genotyping."
87,rosuvastatin,ABCG2,Decreased Function,SLCO1B1,None,"Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific guidelines and specific population guidelines. SLCO1B1 genotype result is not available."
88,rosuvastatin,ABCG2,Poor Function,SLCO1B1,Increased Function,"Prescribe <=20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391)."
89,rosuvastatin,ABCG2,Poor Function,SLCO1B1,Normal Function,"Prescribe <=20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391)."
90,rosuvastatin,ABCG2,Poor Function,SLCO1B1,Possible Decreased Function,"Prescribe <=10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >10mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391)."
91,rosuvastatin,ABCG2,Poor Function,SLCO1B1,Decreased Function,"Prescribe <=10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >10mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391)."
92,rosuvastatin,ABCG2,Poor Function,SLCO1B1,Poor Function,"Prescribe <=10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >10mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391)."
93,rosuvastatin,ABCG2,Poor Function,SLCO1B1,Indeterminate,"Based on ABCG2 status, prescribe <=20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping."
94,rosuvastatin,ABCG2,Poor Function,SLCO1B1,None,"Based on ABCG2 status, prescribe <=20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available."
95,rosuvastatin,ABCG2,None,SLCO1B1,Increased Function,"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. ABCG2 genotype result is not available."
96,rosuvastatin,ABCG2,None,SLCO1B1,Normal Function,"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. ABCG2 genotype result is not available."
97,rosuvastatin,ABCG2,None,SLCO1B1,Possible Decreased Function,"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg. ABCG2 genotype result is not available."
98,rosuvastatin,ABCG2,None,SLCO1B1,Decreased Function,"Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg. ABCG2 genotype result is not available."
99,rosuvastatin,ABCG2,None,SLCO1B1,Poor Function,"Based on SLCO1B1 status, prescribe <=20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines If dose >20mg needed for desired efficacy, consider combination therapy (i.e. rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). ABCG2 genotype result is not available."
100,rosuvastatin,ABCG2,None,SLCO1B1,Indeterminate,None
101,rosuvastatin,ABCG2,None,SLCO1B1,None,None
102,desflurane,CACNA1S,Uncertain Susceptibility,RYR1,Uncertain Susceptibility,"Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants."
103,desflurane,CACNA1S,Uncertain Susceptibility,RYR1,Malignant Hyperthermia Susceptibility,"Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."
104,desflurane,CACNA1S,Uncertain Susceptibility,RYR1,None,None
105,desflurane,CACNA1S,Malignant Hyperthermia Susceptibility,RYR1,Uncertain Susceptibility,"Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."
106,desflurane,CACNA1S,Malignant Hyperthermia Susceptibility,RYR1,Malignant Hyperthermia Susceptibility,None
107,desflurane,CACNA1S,Malignant Hyperthermia Susceptibility,RYR1,None,None
108,desflurane,CACNA1S,None,RYR1,Uncertain Susceptibility,None
109,desflurane,CACNA1S,None,RYR1,Malignant Hyperthermia Susceptibility,None
110,desflurane,CACNA1S,None,RYR1,None,None
111,enflurane,CACNA1S,Uncertain Susceptibility,RYR1,Uncertain Susceptibility,"Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants."
112,enflurane,CACNA1S,Uncertain Susceptibility,RYR1,Malignant Hyperthermia Susceptibility,"Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."
113,enflurane,CACNA1S,Uncertain Susceptibility,RYR1,None,None
114,enflurane,CACNA1S,Malignant Hyperthermia Susceptibility,RYR1,Uncertain Susceptibility,"Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."
115,enflurane,CACNA1S,Malignant Hyperthermia Susceptibility,RYR1,Malignant Hyperthermia Susceptibility,None
116,enflurane,CACNA1S,Malignant Hyperthermia Susceptibility,RYR1,None,None
117,enflurane,CACNA1S,None,RYR1,Uncertain Susceptibility,None
118,enflurane,CACNA1S,None,RYR1,Malignant Hyperthermia Susceptibility,None
119,enflurane,CACNA1S,None,RYR1,None,None
120,halothane,CACNA1S,Uncertain Susceptibility,RYR1,Uncertain Susceptibility,"Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants."
121,halothane,CACNA1S,Uncertain Susceptibility,RYR1,Malignant Hyperthermia Susceptibility,"Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."
122,halothane,CACNA1S,Uncertain Susceptibility,RYR1,None,None
123,halothane,CACNA1S,Malignant Hyperthermia Susceptibility,RYR1,Uncertain Susceptibility,"Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."
124,halothane,CACNA1S,Malignant Hyperthermia Susceptibility,RYR1,Malignant Hyperthermia Susceptibility,None
125,halothane,CACNA1S,Malignant Hyperthermia Susceptibility,RYR1,None,None
126,halothane,CACNA1S,None,RYR1,Uncertain Susceptibility,None
127,halothane,CACNA1S,None,RYR1,Malignant Hyperthermia Susceptibility,None
128,halothane,CACNA1S,None,RYR1,None,None
129,isoflurane,CACNA1S,Uncertain Susceptibility,RYR1,Uncertain Susceptibility,"Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants."
130,isoflurane,CACNA1S,Uncertain Susceptibility,RYR1,Malignant Hyperthermia Susceptibility,"Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."
131,isoflurane,CACNA1S,Uncertain Susceptibility,RYR1,None,None
132,isoflurane,CACNA1S,Malignant Hyperthermia Susceptibility,RYR1,Uncertain Susceptibility,"Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."
133,isoflurane,CACNA1S,Malignant Hyperthermia Susceptibility,RYR1,Malignant Hyperthermia Susceptibility,None
134,isoflurane,CACNA1S,Malignant Hyperthermia Susceptibility,RYR1,None,None
135,isoflurane,CACNA1S,None,RYR1,Uncertain Susceptibility,None
136,isoflurane,CACNA1S,None,RYR1,Malignant Hyperthermia Susceptibility,None
137,isoflurane,CACNA1S,None,RYR1,None,None
138,methoxyflurane,CACNA1S,Uncertain Susceptibility,RYR1,Uncertain Susceptibility,"Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants."
139,methoxyflurane,CACNA1S,Uncertain Susceptibility,RYR1,Malignant Hyperthermia Susceptibility,"Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."
140,methoxyflurane,CACNA1S,Uncertain Susceptibility,RYR1,None,None
141,methoxyflurane,CACNA1S,Malignant Hyperthermia Susceptibility,RYR1,Uncertain Susceptibility,"Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."
142,methoxyflurane,CACNA1S,Malignant Hyperthermia Susceptibility,RYR1,Malignant Hyperthermia Susceptibility,None
143,methoxyflurane,CACNA1S,Malignant Hyperthermia Susceptibility,RYR1,None,None
144,methoxyflurane,CACNA1S,None,RYR1,Uncertain Susceptibility,None
145,methoxyflurane,CACNA1S,None,RYR1,Malignant Hyperthermia Susceptibility,None
146,methoxyflurane,CACNA1S,None,RYR1,None,None
147,sevoflurane,CACNA1S,Uncertain Susceptibility,RYR1,Uncertain Susceptibility,"Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants."
148,sevoflurane,CACNA1S,Uncertain Susceptibility,RYR1,Malignant Hyperthermia Susceptibility,"Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."
149,sevoflurane,CACNA1S,Uncertain Susceptibility,RYR1,None,None
150,sevoflurane,CACNA1S,Malignant Hyperthermia Susceptibility,RYR1,Uncertain Susceptibility,"Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."
151,sevoflurane,CACNA1S,Malignant Hyperthermia Susceptibility,RYR1,Malignant Hyperthermia Susceptibility,None
152,sevoflurane,CACNA1S,Malignant Hyperthermia Susceptibility,RYR1,None,None
153,sevoflurane,CACNA1S,None,RYR1,Uncertain Susceptibility,None
154,sevoflurane,CACNA1S,None,RYR1,Malignant Hyperthermia Susceptibility,None
155,sevoflurane,CACNA1S,None,RYR1,None,None
156,succinylcholine,CACNA1S,Uncertain Susceptibility,RYR1,Uncertain Susceptibility,"Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants."
157,succinylcholine,CACNA1S,Uncertain Susceptibility,RYR1,Malignant Hyperthermia Susceptibility,"Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."
158,succinylcholine,CACNA1S,Uncertain Susceptibility,RYR1,None,None
159,succinylcholine,CACNA1S,Malignant Hyperthermia Susceptibility,RYR1,Uncertain Susceptibility,"Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."
160,succinylcholine,CACNA1S,Malignant Hyperthermia Susceptibility,RYR1,Malignant Hyperthermia Susceptibility,None
161,succinylcholine,CACNA1S,Malignant Hyperthermia Susceptibility,RYR1,None,None
162,succinylcholine,CACNA1S,None,RYR1,Uncertain Susceptibility,None
163,succinylcholine,CACNA1S,None,RYR1,Malignant Hyperthermia Susceptibility,None
164,succinylcholine,CACNA1S,None,RYR1,None,None
165,ivacaftor,CFTR,Favorable Response,None,None,Use ivacaftor according to the product label.
166,ivacaftor,CFTR,Unfavorable Response,None,None,Ivacaftor is not recommended.
167,ivacaftor,CFTR,Indeterminate,None,None,None
168,citalopram,CYP2C19,Ultrarapid Metabolizer,None,None,Consider an alternative drug not predominantly metabolized by CYP2C19.
169,citalopram,CYP2C19,Rapid Metabolizer,None,None,Consider an alternative drug not predominantly metabolized by CYP2C19.
170,citalopram,CYP2C19,Normal Metabolizer,None,None,Initiate therapy with recommended starting dose.
171,citalopram,CYP2C19,Likely Intermediate Metabolizer,None,None,Initiate therapy with recommended starting dose.
172,citalopram,CYP2C19,Intermediate Metabolizer,None,None,Initiate therapy with recommended starting dose.
173,citalopram,CYP2C19,Likely Poor Metabolizer,None,None,Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.
174,citalopram,CYP2C19,Poor Metabolizer,None,None,Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.
175,citalopram,CYP2C19,Indeterminate,None,None,None
176,escitalopram,CYP2C19,Ultrarapid Metabolizer,None,None,Consider an alternative drug not predominantly metabolized by CYP2C19.
177,escitalopram,CYP2C19,Rapid Metabolizer,None,None,Consider an alternative drug not predominantly metabolized by CYP2C19.
178,escitalopram,CYP2C19,Normal Metabolizer,None,None,Initiate therapy with recommended starting dose.
179,escitalopram,CYP2C19,Likely Intermediate Metabolizer,None,None,Initiate therapy with recommended starting dose.
180,escitalopram,CYP2C19,Intermediate Metabolizer,None,None,Initiate therapy with recommended starting dose.
181,escitalopram,CYP2C19,Likely Poor Metabolizer,None,None,Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.
182,escitalopram,CYP2C19,Poor Metabolizer,None,None,Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.
183,escitalopram,CYP2C19,Indeterminate,None,None,None
184,clopidogrel,CYP2C19,Ultrarapid Metabolizer,None,None,"If considering clopidogrel, use at standard dose (75 mg/day)."
185,clopidogrel,CYP2C19,Rapid Metabolizer,None,None,"If considering clopidogrel, use at standard dose (75 mg/day)."
186,clopidogrel,CYP2C19,Normal Metabolizer,None,None,"If considering clopidogrel, use at standard dose (75 mg/day)."
187,clopidogrel,CYP2C19,Likely Intermediate Metabolizer,None,None,Avoid standard dose clopidogrel (75 mg) if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.
188,clopidogrel,CYP2C19,Intermediate Metabolizer,None,None,Avoid standard dose (75 mg) clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.
189,clopidogrel,CYP2C19,Likely Poor Metabolizer,None,None,Avoid standard dose (75 mg/day) clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.
190,clopidogrel,CYP2C19,Poor Metabolizer,None,None,Avoid standard dose (75 mg/day) clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.
191,clopidogrel,CYP2C19,Indeterminate,None,None,None
192,voriconazole,CYP2C19,Ultrarapid Metabolizer,None,None,"Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole."
193,voriconazole,CYP2C19,Rapid Metabolizer,None,None,"Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole."
194,voriconazole,CYP2C19,Normal Metabolizer,None,None,Initiate therapy with recommended standard of care dosing.
195,voriconazole,CYP2C19,Likely Intermediate Metabolizer,None,None,Initiate therapy with recommended standard of care dosing.
196,voriconazole,CYP2C19,Intermediate Metabolizer,None,None,Initiate therapy with recommended standard of care dosing.
197,voriconazole,CYP2C19,Likely Poor Metabolizer,None,None,"Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring."
198,voriconazole,CYP2C19,Poor Metabolizer,None,None,"Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring."
199,voriconazole,CYP2C19,Indeterminate,None,None,None
200,sertraline,CYP2C19,Ultrarapid Metabolizer,None,None,"Initiate therapy with recommended starting dose. If patient does not respond to recommended maintenance dosing, consider alternative drug not predominantly metabolized by CYP2C19."
201,sertraline,CYP2C19,Rapid Metabolizer,None,None,"Initiate therapy with recommended starting dose. If patient does not respond to recommended maintenance dosing, consider alternative drug not predominantly metabolized by CYP2C19."
202,sertraline,CYP2C19,Normal Metabolizer,None,None,Initiate therapy with recommended starting dose.
203,sertraline,CYP2C19,Likely Intermediate Metabolizer,None,None,Initiate therapy with recommended starting dose.
204,sertraline,CYP2C19,Intermediate Metabolizer,None,None,Initiate therapy with recommended starting dose.
205,sertraline,CYP2C19,Likely Poor Metabolizer,None,None,Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.
206,sertraline,CYP2C19,Poor Metabolizer,None,None,Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.
207,sertraline,CYP2C19,Indeterminate,None,None,None
208,lansoprazole,CYP2C19,Ultrarapid Metabolizer,None,None,Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.
209,lansoprazole,CYP2C19,Rapid Metabolizer,None,None,Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.
210,lansoprazole,CYP2C19,Normal Metabolizer,None,None,Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.
211,lansoprazole,CYP2C19,Likely Intermediate Metabolizer,None,None,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."
212,lansoprazole,CYP2C19,Intermediate Metabolizer,None,None,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."
213,lansoprazole,CYP2C19,Likely Poor Metabolizer,None,None,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."
214,lansoprazole,CYP2C19,Poor Metabolizer,None,None,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."
215,lansoprazole,CYP2C19,Indeterminate,None,None,None
216,omeprazole,CYP2C19,Ultrarapid Metabolizer,None,None,Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.
217,omeprazole,CYP2C19,Rapid Metabolizer,None,None,Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.
218,omeprazole,CYP2C19,Normal Metabolizer,None,None,Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.
219,omeprazole,CYP2C19,Likely Intermediate Metabolizer,None,None,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."
220,omeprazole,CYP2C19,Intermediate Metabolizer,None,None,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."
221,omeprazole,CYP2C19,Likely Poor Metabolizer,None,None,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."
222,omeprazole,CYP2C19,Poor Metabolizer,None,None,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."
223,omeprazole,CYP2C19,Indeterminate,None,None,None
224,pantoprazole,CYP2C19,Ultrarapid Metabolizer,None,None,Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.
225,pantoprazole,CYP2C19,Rapid Metabolizer,None,None,Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.
226,pantoprazole,CYP2C19,Normal Metabolizer,None,None,Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.
227,pantoprazole,CYP2C19,Likely Intermediate Metabolizer,None,None,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."
228,pantoprazole,CYP2C19,Intermediate Metabolizer,None,None,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."
229,pantoprazole,CYP2C19,Likely Poor Metabolizer,None,None,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."
230,pantoprazole,CYP2C19,Poor Metabolizer,None,None,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."
231,pantoprazole,CYP2C19,Indeterminate,None,None,None
232,dexlansoprazole,CYP2C19,Ultrarapid Metabolizer,None,None,Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.
233,dexlansoprazole,CYP2C19,Rapid Metabolizer,None,None,Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.
234,dexlansoprazole,CYP2C19,Normal Metabolizer,None,None,Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.
235,dexlansoprazole,CYP2C19,Likely Intermediate Metabolizer,None,None,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."
236,dexlansoprazole,CYP2C19,Intermediate Metabolizer,None,None,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."
237,dexlansoprazole,CYP2C19,Likely Poor Metabolizer,None,None,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."
238,dexlansoprazole,CYP2C19,Poor Metabolizer,None,None,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."
239,dexlansoprazole,CYP2C19,Indeterminate,None,None,None
240,capecitabine,DPYD,Normal Metabolizer,None,None,"Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration."
241,capecitabine,DPYD,Intermediate Metabolizer,None,None,Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).
242,capecitabine,DPYD,Poor Metabolizer,None,None,Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.
243,fluorouracil,DPYD,Normal Metabolizer,None,None,"Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration."
244,fluorouracil,DPYD,Intermediate Metabolizer,None,None,Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).
245,fluorouracil,DPYD,Poor Metabolizer,None,None,Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.
246,hormonal contraceptives for systemic use,F5,Favorable Response,None,None,The guideline does not provide a recommendation for estrogen-containing contraceptives in patients who do not have the Factor V Leiden variant.
247,hormonal contraceptives for systemic use,F5,Unfavorable Response,None,None,"If the patient has a FAMILY HISTORY WITH A LOT OF THROMBOSIS, or has had a PREVIOUS THROMBOSIS: Advise the prescriber to avoid the use of contraceptives that contain oestrogens and prescribe a non-hormone contraceptive - such as a copper IUD - as an alternative. One could also opt for a progestogen-only contraceptive method, such as the depot injection, an IUD with levonorgestrel or an implant with etonogestrel. OTHER CASES: Advise the patient to avoid additional risk factors for thrombosis (obesity, smoking, etc.)."
248,peginterferon alfa-2a,IFNL3,Favorable Response,None,None,IMPLICATIONS FOR PEG-IFN ALPHA AND RBV: Approximately 70% chance for SVR after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens. Approximately 90% chance for SVR after 24-48 weeks of treatment. IMPLICATIONS FOR PROTEASE INHIBITOR COMBINATIONS WITH PEG-IFN ALPHA AND RBV THERAPY: Approximately 80-90% of patients are eligible for shortened therapy (24-28 weeks vs. 48 weeks). Weighs in favor of using PEG-IFN alpha and RBV containing regimens.
249,peginterferon alfa-2a,IFNL3,Unfavorable Response,None,None,IMPLICATIONS FOR PEG-IFN ALPHA AND RBV: Approximately 30% chance for SVR after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens. IMPLICATIONS FOR PROTEASE INHIBITOR COMBINATIONS WITH PEG-IFN ALPHA AND RBV THERAPY: Approximately 60% chance for SVR after 24-48 weeks of treatment. Approximately 50% of patients are eligible for shortened therapy (24-28 weeks). Consider implications before initiating PEG-IFN and RBV containing regimens.
250,peginterferon alfa-2a,IFNL3,Indeterminate,None,None,None
251,peginterferon alfa-2b,IFNL3,Favorable Response,None,None,IMPLICATIONS FOR PEG-IFN ALPHA AND RBV: Approximately 70% chance for SVR after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens. Approximately 90% chance for SVR after 24-48 weeks of treatment. IMPLICATIONS FOR PROTEASE INHIBITOR COMBINATIONS WITH PEG-IFN ALPHA AND RBV THERAPY: Approximately 80-90% of patients are eligible for shortened therapy (24-28 weeks vs. 48 weeks). Weighs in favor of using PEG-IFN alpha and RBV containing regimens.
252,peginterferon alfa-2b,IFNL3,Unfavorable Response,None,None,IMPLICATIONS FOR PEG-IFN ALPHA AND RBV: Approximately 30% chance for SVR after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens. IMPLICATIONS FOR PROTEASE INHIBITOR COMBINATIONS WITH PEG-IFN ALPHA AND RBV THERAPY: Approximately 60% chance for SVR after 24-48 weeks of treatment. Approximately 50% of patients are eligible for shortened therapy (24-28 weeks). Consider implications before initiating PEG-IFN and RBV containing regimens.
253,peginterferon alfa-2b,IFNL3,Indeterminate,None,None,None
254,ribavirin,IFNL3,Favorable Response,None,None,IMPLICATIONS FOR PEG-IFN ALPHA AND RBV: Approximately 70% chance for SVR after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens. Approximately 90% chance for SVR after 24-48 weeks of treatment. IMPLICATIONS FOR PROTEASE INHIBITOR COMBINATIONS WITH PEG-IFN ALPHA AND RBV THERAPY: Approximately 80-90% of patients are eligible for shortened therapy (24-28 weeks vs. 48 weeks). Weighs in favor of using PEG-IFN alpha and RBV containing regimens.
255,ribavirin,IFNL3,Unfavorable Response,None,None,IMPLICATIONS FOR PEG-IFN ALPHA AND RBV: Approximately 30% chance for SVR after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens. IMPLICATIONS FOR PROTEASE INHIBITOR COMBINATIONS WITH PEG-IFN ALPHA AND RBV THERAPY: Approximately 60% chance for SVR after 24-48 weeks of treatment. Approximately 50% of patients are eligible for shortened therapy (24-28 weeks). Consider implications before initiating PEG-IFN and RBV containing regimens.
256,ribavirin,IFNL3,Indeterminate,None,None,None
257,azathioprine,NUDT15,Normal Metabolizer,TPMT,Normal Metabolizer,"Start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506)."
258,azathioprine,NUDT15,Normal Metabolizer,TPMT,Possible Intermediate Metabolizer,"Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 - 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532)."
259,azathioprine,NUDT15,Normal Metabolizer,TPMT,Intermediate Metabolizer,"Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 - 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532)."
260,azathioprine,NUDT15,Normal Metabolizer,TPMT,Poor Metabolizer,"For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776)."
261,azathioprine,NUDT15,Normal Metabolizer,TPMT,Indeterminate,"Based on NUDT15, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity."
262,azathioprine,NUDT15,Normal Metabolizer,TPMT,None,"Based on NUDT15, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity."
263,azathioprine,NUDT15,Intermediate Metabolizer,TPMT,Normal Metabolizer,"Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 - 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532)."
264,azathioprine,NUDT15,Intermediate Metabolizer,TPMT,Possible Intermediate Metabolizer,"Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 - 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532)."
265,azathioprine,NUDT15,Intermediate Metabolizer,TPMT,Intermediate Metabolizer,"Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 - 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532)."
266,azathioprine,NUDT15,Intermediate Metabolizer,TPMT,Poor Metabolizer,"For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776)."
267,azathioprine,NUDT15,Intermediate Metabolizer,TPMT,Indeterminate,"Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 - 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity."
268,azathioprine,NUDT15,Intermediate Metabolizer,TPMT,None,"Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 - 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity."
269,azathioprine,NUDT15,Possible Intermediate Metabolizer,TPMT,Normal Metabolizer,"Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 - 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532)."
270,azathioprine,NUDT15,Possible Intermediate Metabolizer,TPMT,Possible Intermediate Metabolizer,"Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 - 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532)."
271,azathioprine,NUDT15,Possible Intermediate Metabolizer,TPMT,Intermediate Metabolizer,"Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 - 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532)."
272,azathioprine,NUDT15,Possible Intermediate Metabolizer,TPMT,Poor Metabolizer,"For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776)."
273,azathioprine,NUDT15,Possible Intermediate Metabolizer,TPMT,Indeterminate,"Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 - 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity."
274,azathioprine,NUDT15,Possible Intermediate Metabolizer,TPMT,None,"Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 - 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity."
275,azathioprine,NUDT15,Poor Metabolizer,TPMT,Normal Metabolizer,"For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776)."
276,azathioprine,NUDT15,Poor Metabolizer,TPMT,Possible Intermediate Metabolizer,"For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776)."
277,azathioprine,NUDT15,Poor Metabolizer,TPMT,Intermediate Metabolizer,"For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776)."
278,azathioprine,NUDT15,Poor Metabolizer,TPMT,Poor Metabolizer,"For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776)."
279,azathioprine,NUDT15,Poor Metabolizer,TPMT,Indeterminate,"Based on NUDT15 status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity."
280,azathioprine,NUDT15,Poor Metabolizer,TPMT,None,"Based on NUDT15 status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity."
281,azathioprine,NUDT15,Indeterminate,TPMT,Normal Metabolizer,"Based on TPMT status, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity."
282,azathioprine,NUDT15,Indeterminate,TPMT,Possible Intermediate Metabolizer,"Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 - 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
283,azathioprine,NUDT15,Indeterminate,TPMT,Intermediate Metabolizer,"Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 - 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity."
284,azathioprine,NUDT15,Indeterminate,TPMT,Poor Metabolizer,"Based on TPMT status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity."
285,azathioprine,NUDT15,Indeterminate,TPMT,Indeterminate,"Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
286,azathioprine,NUDT15,Indeterminate,TPMT,None,"NUDT15 phenotype could not be assigned based on genotyping performed and no TPMT genotype is available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
287,azathioprine,NUDT15,None,TPMT,Normal Metabolizer,"Based on TPMT status, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity."
288,azathioprine,NUDT15,None,TPMT,Possible Intermediate Metabolizer,"Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 - 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). NUDT15 genotype is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
289,azathioprine,NUDT15,None,TPMT,Intermediate Metabolizer,"Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 - 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity."
290,azathioprine,NUDT15,None,TPMT,Poor Metabolizer,"Based on TPMT status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity."
291,azathioprine,NUDT15,None,TPMT,Indeterminate,"TPMT phenotype could not be assigned based on genotyping performed and NUDT15 genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
292,azathioprine,NUDT15,None,TPMT,None,None
293,mercaptopurine,NUDT15,Normal Metabolizer,TPMT,Normal Metabolizer,"Start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950)."
294,mercaptopurine,NUDT15,Normal Metabolizer,TPMT,Possible Intermediate Metabolizer,"Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is >= 75 mg/m2/day or >= 1.5 mg/kg/day (e.g. start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended."
295,mercaptopurine,NUDT15,Normal Metabolizer,TPMT,Intermediate Metabolizer,"Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is >= 75 mg/m2/day or >= 1.5 mg/kg/day (e.g. start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended."
296,mercaptopurine,NUDT15,Normal Metabolizer,TPMT,Poor Metabolizer,"For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532)."
297,mercaptopurine,NUDT15,Normal Metabolizer,TPMT,Indeterminate,"Based on NUDT15 status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity."
298,mercaptopurine,NUDT15,Normal Metabolizer,TPMT,None,"Based on NUDT15 status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). TPMT genotype result is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity."
299,mercaptopurine,NUDT15,Intermediate Metabolizer,TPMT,Normal Metabolizer,"Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is >=75 mg/m2/day or >= 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended."
300,mercaptopurine,NUDT15,Intermediate Metabolizer,TPMT,Possible Intermediate Metabolizer,"Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is >= 75 mg/m2/day or >= 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended."
301,mercaptopurine,NUDT15,Intermediate Metabolizer,TPMT,Intermediate Metabolizer,"Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is >= 75 mg/m2/day or >= 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended."
302,mercaptopurine,NUDT15,Intermediate Metabolizer,TPMT,Poor Metabolizer,"For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532)."
303,mercaptopurine,NUDT15,Intermediate Metabolizer,TPMT,Indeterminate,"Based NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is >=75 mg/m2/day or >= 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. TPMT phenotype could not be assigned based on genotyping. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
304,mercaptopurine,NUDT15,Intermediate Metabolizer,TPMT,None,"Based NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is >=75 mg/m2/day or >= 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. TPMT genotype result is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
305,mercaptopurine,NUDT15,Possible Intermediate Metabolizer,TPMT,Normal Metabolizer,"Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is >=75 mg/m2/day or >= 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended."
306,mercaptopurine,NUDT15,Possible Intermediate Metabolizer,TPMT,Possible Intermediate Metabolizer,"Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is >= 75 mg/m2/day or >= 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended."
307,mercaptopurine,NUDT15,Possible Intermediate Metabolizer,TPMT,Intermediate Metabolizer,"Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is >= 75 mg/m2/day or >= 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended."
308,mercaptopurine,NUDT15,Possible Intermediate Metabolizer,TPMT,Poor Metabolizer,"For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532)."
309,mercaptopurine,NUDT15,Possible Intermediate Metabolizer,TPMT,Indeterminate,"Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is >=75 mg/m2/day or >= 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity."
310,mercaptopurine,NUDT15,Possible Intermediate Metabolizer,TPMT,None,"Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is >=75 mg/m2/day or >= 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. TPMT genotype result is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity."
311,mercaptopurine,NUDT15,Poor Metabolizer,TPMT,Normal Metabolizer,"For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532)."
312,mercaptopurine,NUDT15,Poor Metabolizer,TPMT,Possible Intermediate Metabolizer,"For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532)."
313,mercaptopurine,NUDT15,Poor Metabolizer,TPMT,Intermediate Metabolizer,"For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532)."
314,mercaptopurine,NUDT15,Poor Metabolizer,TPMT,Poor Metabolizer,"For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532)."
315,mercaptopurine,NUDT15,Poor Metabolizer,TPMT,Indeterminate,"Based on NUDT15 status, for malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity."
316,mercaptopurine,NUDT15,Poor Metabolizer,TPMT,None,"Based on NUDT15 status, for malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532). TPMT genotype result is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity."
317,mercaptopurine,NUDT15,Indeterminate,TPMT,Normal Metabolizer,"Based on TPMT status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
318,mercaptopurine,NUDT15,Indeterminate,TPMT,Possible Intermediate Metabolizer,"Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is >= 75 mg/m2/day or >= 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
319,mercaptopurine,NUDT15,Indeterminate,TPMT,Intermediate Metabolizer,"Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is >= 75 mg/m2/day or >= 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
320,mercaptopurine,NUDT15,Indeterminate,TPMT,Poor Metabolizer,"Based on TPMT status, for malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
321,mercaptopurine,NUDT15,Indeterminate,TPMT,Indeterminate,"Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
322,mercaptopurine,NUDT15,Indeterminate,TPMT,None,"NUDT15 phenotype could not be assigned based on genotyping performed and there is no TPMT genotype result result. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
323,mercaptopurine,NUDT15,None,TPMT,Normal Metabolizer,"Based on TPMT status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). NUDT15 genotype result is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
324,mercaptopurine,NUDT15,None,TPMT,Possible Intermediate Metabolizer,"Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is >= 75 mg/m2/day or >= 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 genotype result is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
325,mercaptopurine,NUDT15,None,TPMT,Intermediate Metabolizer,"Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is >= 75 mg/m2/day or >= 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 genotype result is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
326,mercaptopurine,NUDT15,None,TPMT,Poor Metabolizer,"Based on TPMT status, for malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532). NUDT15 genotype result is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
327,mercaptopurine,NUDT15,None,TPMT,Indeterminate,"TPMT phenotype could not be assigned based on genotyping performed and there is no NUDT15 genotype result available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
328,mercaptopurine,NUDT15,None,TPMT,None,None
329,thioguanine,NUDT15,Normal Metabolizer,TPMT,Normal Metabolizer,"Start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11037857)."
330,thioguanine,NUDT15,Normal Metabolizer,TPMT,Possible Intermediate Metabolizer,"Start with reduced doses (50% to 80% of normal dose) if normal starting dose is >= 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857)."
331,thioguanine,NUDT15,Normal Metabolizer,TPMT,Intermediate Metabolizer,"Start with reduced doses (50% to 80% of normal dose) if normal starting dose is >= 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857)."
332,thioguanine,NUDT15,Normal Metabolizer,TPMT,Poor Metabolizer,"Start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201)."
333,thioguanine,NUDT15,Normal Metabolizer,TPMT,Indeterminate,"Based on NUDT15, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11037857). However, TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity."
334,thioguanine,NUDT15,Normal Metabolizer,TPMT,None,"Based on NUDT15, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11037857). However, TPMT genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity."
335,thioguanine,NUDT15,Intermediate Metabolizer,TPMT,Normal Metabolizer,"Start with reduced doses (50% to 80% of normal dose) if normal starting dose is >= 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857)."
336,thioguanine,NUDT15,Intermediate Metabolizer,TPMT,Possible Intermediate Metabolizer,"Start with reduced doses (50% to 80% of normal dose) if normal starting dose is >= 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857)."
337,thioguanine,NUDT15,Intermediate Metabolizer,TPMT,Intermediate Metabolizer,"Start with reduced doses (50% to 80% of normal dose) if normal starting dose is >= 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857)."
338,thioguanine,NUDT15,Intermediate Metabolizer,TPMT,Poor Metabolizer,"Start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201)."
339,thioguanine,NUDT15,Intermediate Metabolizer,TPMT,Indeterminate,"Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is >= 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity."
340,thioguanine,NUDT15,Intermediate Metabolizer,TPMT,None,"Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is >= 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity."
341,thioguanine,NUDT15,Possible Intermediate Metabolizer,TPMT,Normal Metabolizer,"Start with reduced doses (50% to 80% of normal dose) if normal starting dose is >= 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857)."
342,thioguanine,NUDT15,Possible Intermediate Metabolizer,TPMT,Possible Intermediate Metabolizer,"Start with reduced doses (50% to 80% of normal dose) if normal starting dose is >= 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857)."
343,thioguanine,NUDT15,Possible Intermediate Metabolizer,TPMT,Intermediate Metabolizer,"Start with reduced doses (50% to 80% of normal dose) if normal starting dose is >= 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857)."
344,thioguanine,NUDT15,Possible Intermediate Metabolizer,TPMT,Poor Metabolizer,"Start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201)."
345,thioguanine,NUDT15,Possible Intermediate Metabolizer,TPMT,Indeterminate,"Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is >= 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
346,thioguanine,NUDT15,Possible Intermediate Metabolizer,TPMT,None,"Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is >= 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
347,thioguanine,NUDT15,Poor Metabolizer,TPMT,Normal Metabolizer,"Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201)."
348,thioguanine,NUDT15,Poor Metabolizer,TPMT,Possible Intermediate Metabolizer,"Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201)."
349,thioguanine,NUDT15,Poor Metabolizer,TPMT,Intermediate Metabolizer,"Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201)."
350,thioguanine,NUDT15,Poor Metabolizer,TPMT,Poor Metabolizer,"Start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201)."
351,thioguanine,NUDT15,Poor Metabolizer,TPMT,Indeterminate,"Based on NUDT15, reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity."
352,thioguanine,NUDT15,Poor Metabolizer,TPMT,None,"Based on NUDT15, reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201). TPMT genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity."
353,thioguanine,NUDT15,Indeterminate,TPMT,Normal Metabolizer,"Based on TPMT status, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 203542+J1301, 11037857). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity."
354,thioguanine,NUDT15,Indeterminate,TPMT,Possible Intermediate Metabolizer,"Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is >= 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
355,thioguanine,NUDT15,Indeterminate,TPMT,Intermediate Metabolizer,"Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is >= 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity."
356,thioguanine,NUDT15,Indeterminate,TPMT,Poor Metabolizer,"Based on TPMT status, start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity."
357,thioguanine,NUDT15,Indeterminate,TPMT,Indeterminate,"Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
358,thioguanine,NUDT15,Indeterminate,TPMT,None,"NUDT15 phenotype could not be assigned based on genotyping performed and there is no TPMT genotype available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
359,thioguanine,NUDT15,None,TPMT,Normal Metabolizer,"Based on TPMT status, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 203542+J1301, 11037857). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity."
360,thioguanine,NUDT15,None,TPMT,Possible Intermediate Metabolizer,"Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is >= 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). NUDT15 genotype is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
361,thioguanine,NUDT15,None,TPMT,Intermediate Metabolizer,"Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is >= 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity."
362,thioguanine,NUDT15,None,TPMT,Poor Metabolizer,"Based on TPMT status, start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity."
363,thioguanine,NUDT15,None,TPMT,Indeterminate,"TPMT phenotype could not be assigned based on genotyping performed and NUDT15 genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity."
364,thioguanine,NUDT15,None,TPMT,None,None
365,atorvastatin,SLCO1B1,Increased Function,None,None,Prescribe desired starting dose and adjust doses based on disease-specific guidelines.
366,atorvastatin,SLCO1B1,Normal Function,None,None,Prescribe desired starting dose and adjust doses based on disease-specific guidelines.
367,atorvastatin,SLCO1B1,Possible Decreased Function,None,None,"Prescribe <=40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose >40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391)."
368,atorvastatin,SLCO1B1,Decreased Function,None,None,"Prescribe <=40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose >40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391)."
369,atorvastatin,SLCO1B1,Poor Function,None,None,"Prescribe <=20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391)."
370,atorvastatin,SLCO1B1,Indeterminate,None,None,None
371,lovastatin,SLCO1B1,Increased Function,None,None,Prescribe desired starting dose and adjust doses based on disease-specific guidelines.
372,lovastatin,SLCO1B1,Normal Function,None,None,Prescribe desired starting dose and adjust doses based on disease-specific guidelines.
373,lovastatin,SLCO1B1,Possible Decreased Function,None,None,"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to <=20mg/day."
374,lovastatin,SLCO1B1,Decreased Function,None,None,"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to <=20mg/day."
375,lovastatin,SLCO1B1,Poor Function,None,None,Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).
376,lovastatin,SLCO1B1,Indeterminate,None,None,None
377,pitavastatin,SLCO1B1,Increased Function,None,None,Prescribe desired starting dose and adjust doses based on disease-specific guidelines.
378,pitavastatin,SLCO1B1,Normal Function,None,None,Prescribe desired starting dose and adjust doses based on disease-specific guidelines.
379,pitavastatin,SLCO1B1,Possible Decreased Function,None,None,"Prescribe <= 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >1mg. If dose >2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391)."
380,pitavastatin,SLCO1B1,Decreased Function,None,None,"Prescribe <= 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >1mg. If dose >2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391)."
381,pitavastatin,SLCO1B1,Poor Function,None,None,"Prescribe <=1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If dose >1mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy)(PMID: 30423391)."
382,pitavastatin,SLCO1B1,Indeterminate,None,None,None
383,pravastatin,SLCO1B1,Increased Function,None,None,Prescribe desired starting dose and adjust doses based on disease-specific guidelines.
384,pravastatin,SLCO1B1,Normal Function,None,None,Prescribe desired starting dose and adjust doses based on disease-specific guidelines.
385,pravastatin,SLCO1B1,Possible Decreased Function,None,None,Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.
386,pravastatin,SLCO1B1,Decreased Function,None,None,Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.
387,pravastatin,SLCO1B1,Poor Function,None,None,"Prescribe <=40mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If patient is tolerating 40mg dose but higher potency is needed, a higher dose (>40mg) or an alternative statin (see Figure 1 of of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pravastatin plus non-statin guideline directed medical therapy)(PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy especially with pravastatin doses >40mg."
388,pravastatin,SLCO1B1,Indeterminate,None,None,None
389,simvastatin,SLCO1B1,Increased Function,None,None,Prescribe desired starting dose and adjust doses based on disease-specific guidelines.
390,simvastatin,SLCO1B1,Normal Function,None,None,Prescribe desired starting dose and adjust doses based on disease-specific guidelines.
391,simvastatin,SLCO1B1,Possible Decreased Function,None,None,"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to <20mg/day."
392,simvastatin,SLCO1B1,Decreased Function,None,None,"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to <20mg/day."
393,simvastatin,SLCO1B1,Poor Function,None,None,Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).
394,simvastatin,SLCO1B1,Indeterminate,None,None,None
395,atazanavir,UGT1A1,Normal Metabolizer,None,None,"There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient's genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice)."
396,atazanavir,UGT1A1,Intermediate Metabolizer,None,None,"There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient's genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice)."
397,atazanavir,UGT1A1,Poor Metabolizer,None,None,"Consider an alternative agent particularly where jaundice would be of concern to the patient. If atazanavir is to be prescribed, there is a high likelihood of developing jaundice that will result in atazanavir discontinuation (at least 20% and as high as 60%)."
398,atazanavir,UGT1A1,Indeterminate,None,None,None
399,amitriptyline,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
400,amitriptyline,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Normal Metabolizer,"Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment."
401,amitriptyline,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Intermediate Metabolizer,"Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
402,amitriptyline,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Poor Metabolizer,"Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
403,amitriptyline,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Indeterminate,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."
404,amitriptyline,CYP2C19,Ultrarapid Metabolizer,CYP2D6,None,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."
405,amitriptyline,CYP2C19,Rapid Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
406,amitriptyline,CYP2C19,Rapid Metabolizer,CYP2D6,Normal Metabolizer,"Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment."
407,amitriptyline,CYP2C19,Rapid Metabolizer,CYP2D6,Intermediate Metabolizer,"Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
408,amitriptyline,CYP2C19,Rapid Metabolizer,CYP2D6,Poor Metabolizer,"Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
409,amitriptyline,CYP2C19,Rapid Metabolizer,CYP2D6,Indeterminate,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."
410,amitriptyline,CYP2C19,Rapid Metabolizer,CYP2D6,None,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."
411,amitriptyline,CYP2C19,Normal Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment."
412,amitriptyline,CYP2C19,Normal Metabolizer,CYP2D6,Normal Metabolizer,Initiate therapy with recommended starting dose.
413,amitriptyline,CYP2C19,Normal Metabolizer,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
414,amitriptyline,CYP2C19,Normal Metabolizer,CYP2D6,Poor Metabolizer,"Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."
415,amitriptyline,CYP2C19,Normal Metabolizer,CYP2D6,Indeterminate,None
416,amitriptyline,CYP2C19,Normal Metabolizer,CYP2D6,None,Initiate therapy with recommended starting dose.
417,amitriptyline,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
418,amitriptyline,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Normal Metabolizer,Initiate therapy with recommended starting dose.
419,amitriptyline,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
420,amitriptyline,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Poor Metabolizer,"Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
421,amitriptyline,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Indeterminate,None
422,amitriptyline,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,None,Initiate therapy with recommended starting dose.
423,amitriptyline,CYP2C19,Intermediate Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
424,amitriptyline,CYP2C19,Intermediate Metabolizer,CYP2D6,Normal Metabolizer,Initiate therapy with recommended starting dose.
425,amitriptyline,CYP2C19,Intermediate Metabolizer,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
426,amitriptyline,CYP2C19,Intermediate Metabolizer,CYP2D6,Poor Metabolizer,"Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
427,amitriptyline,CYP2C19,Intermediate Metabolizer,CYP2D6,Indeterminate,None
428,amitriptyline,CYP2C19,Intermediate Metabolizer,CYP2D6,None,Initiate therapy with recommended starting dose.
429,amitriptyline,CYP2C19,Likely Poor Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
430,amitriptyline,CYP2C19,Likely Poor Metabolizer,CYP2D6,Normal Metabolizer,"Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."
431,amitriptyline,CYP2C19,Likely Poor Metabolizer,CYP2D6,Intermediate Metabolizer,"Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
432,amitriptyline,CYP2C19,Likely Poor Metabolizer,CYP2D6,Poor Metabolizer,"Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
433,amitriptyline,CYP2C19,Likely Poor Metabolizer,CYP2D6,Indeterminate,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
434,amitriptyline,CYP2C19,Likely Poor Metabolizer,CYP2D6,None,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
435,amitriptyline,CYP2C19,Poor Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
436,amitriptyline,CYP2C19,Poor Metabolizer,CYP2D6,Normal Metabolizer,"Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."
437,amitriptyline,CYP2C19,Poor Metabolizer,CYP2D6,Intermediate Metabolizer,"Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
438,amitriptyline,CYP2C19,Poor Metabolizer,CYP2D6,Poor Metabolizer,"Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
439,amitriptyline,CYP2C19,Poor Metabolizer,CYP2D6,Indeterminate,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
440,amitriptyline,CYP2C19,Poor Metabolizer,CYP2D6,None,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
441,amitriptyline,CYP2C19,Indeterminate,CYP2D6,Ultrarapid Metabolizer,"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
442,amitriptyline,CYP2C19,Indeterminate,CYP2D6,Normal Metabolizer,None
443,amitriptyline,CYP2C19,Indeterminate,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
444,amitriptyline,CYP2C19,Indeterminate,CYP2D6,Poor Metabolizer,"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
445,amitriptyline,CYP2C19,Indeterminate,CYP2D6,Indeterminate,None
446,amitriptyline,CYP2C19,Indeterminate,CYP2D6,None,None
447,amitriptyline,CYP2C19,None,CYP2D6,Ultrarapid Metabolizer,"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
448,amitriptyline,CYP2C19,None,CYP2D6,Normal Metabolizer,Initiate therapy with recommended starting dose.
449,amitriptyline,CYP2C19,None,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
450,amitriptyline,CYP2C19,None,CYP2D6,Poor Metabolizer,"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
451,amitriptyline,CYP2C19,None,CYP2D6,Indeterminate,None
452,amitriptyline,CYP2C19,None,CYP2D6,None,None
453,clomipramine,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
454,clomipramine,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Normal Metabolizer,"Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment."
455,clomipramine,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Intermediate Metabolizer,"Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
456,clomipramine,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Poor Metabolizer,"Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
457,clomipramine,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Indeterminate,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."
458,clomipramine,CYP2C19,Ultrarapid Metabolizer,CYP2D6,None,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."
459,clomipramine,CYP2C19,Rapid Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
460,clomipramine,CYP2C19,Rapid Metabolizer,CYP2D6,Normal Metabolizer,"Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment."
461,clomipramine,CYP2C19,Rapid Metabolizer,CYP2D6,Intermediate Metabolizer,"Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
462,clomipramine,CYP2C19,Rapid Metabolizer,CYP2D6,Poor Metabolizer,"Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
463,clomipramine,CYP2C19,Rapid Metabolizer,CYP2D6,Indeterminate,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."
464,clomipramine,CYP2C19,Rapid Metabolizer,CYP2D6,None,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."
465,clomipramine,CYP2C19,Normal Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment."
466,clomipramine,CYP2C19,Normal Metabolizer,CYP2D6,Normal Metabolizer,Initiate therapy with recommended starting dose.
467,clomipramine,CYP2C19,Normal Metabolizer,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
468,clomipramine,CYP2C19,Normal Metabolizer,CYP2D6,Poor Metabolizer,"Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."
469,clomipramine,CYP2C19,Normal Metabolizer,CYP2D6,Indeterminate,None
470,clomipramine,CYP2C19,Normal Metabolizer,CYP2D6,None,Initiate therapy with recommended starting dose.
471,clomipramine,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
472,clomipramine,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Normal Metabolizer,Initiate therapy with recommended starting dose.
473,clomipramine,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
474,clomipramine,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Poor Metabolizer,"Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
475,clomipramine,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Indeterminate,None
476,clomipramine,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,None,Initiate therapy with recommended starting dose.
477,clomipramine,CYP2C19,Intermediate Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
478,clomipramine,CYP2C19,Intermediate Metabolizer,CYP2D6,Normal Metabolizer,Initiate therapy with recommended starting dose.
479,clomipramine,CYP2C19,Intermediate Metabolizer,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
480,clomipramine,CYP2C19,Intermediate Metabolizer,CYP2D6,Poor Metabolizer,"Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
481,clomipramine,CYP2C19,Intermediate Metabolizer,CYP2D6,Indeterminate,None
482,clomipramine,CYP2C19,Intermediate Metabolizer,CYP2D6,None,Initiate therapy with recommended starting dose.
483,clomipramine,CYP2C19,Likely Poor Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
484,clomipramine,CYP2C19,Likely Poor Metabolizer,CYP2D6,Normal Metabolizer,"Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."
485,clomipramine,CYP2C19,Likely Poor Metabolizer,CYP2D6,Intermediate Metabolizer,"Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
486,clomipramine,CYP2C19,Likely Poor Metabolizer,CYP2D6,Poor Metabolizer,"Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
487,clomipramine,CYP2C19,Likely Poor Metabolizer,CYP2D6,Indeterminate,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
488,clomipramine,CYP2C19,Likely Poor Metabolizer,CYP2D6,None,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
489,clomipramine,CYP2C19,Poor Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
490,clomipramine,CYP2C19,Poor Metabolizer,CYP2D6,Normal Metabolizer,"Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."
491,clomipramine,CYP2C19,Poor Metabolizer,CYP2D6,Intermediate Metabolizer,"Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
492,clomipramine,CYP2C19,Poor Metabolizer,CYP2D6,Poor Metabolizer,"Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
493,clomipramine,CYP2C19,Poor Metabolizer,CYP2D6,Indeterminate,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
494,clomipramine,CYP2C19,Poor Metabolizer,CYP2D6,None,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
495,clomipramine,CYP2C19,Indeterminate,CYP2D6,Ultrarapid Metabolizer,"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
496,clomipramine,CYP2C19,Indeterminate,CYP2D6,Normal Metabolizer,None
497,clomipramine,CYP2C19,Indeterminate,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
498,clomipramine,CYP2C19,Indeterminate,CYP2D6,Poor Metabolizer,"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
499,clomipramine,CYP2C19,Indeterminate,CYP2D6,Indeterminate,None
500,clomipramine,CYP2C19,Indeterminate,CYP2D6,None,None
501,clomipramine,CYP2C19,None,CYP2D6,Ultrarapid Metabolizer,"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
502,clomipramine,CYP2C19,None,CYP2D6,Normal Metabolizer,Initiate therapy with recommended starting dose.
503,clomipramine,CYP2C19,None,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
504,clomipramine,CYP2C19,None,CYP2D6,Poor Metabolizer,"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
505,clomipramine,CYP2C19,None,CYP2D6,Indeterminate,None
506,clomipramine,CYP2C19,None,CYP2D6,None,None
507,doxepin,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
508,doxepin,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Normal Metabolizer,"Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment."
509,doxepin,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Intermediate Metabolizer,"Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
510,doxepin,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Poor Metabolizer,"Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
511,doxepin,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Indeterminate,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."
512,doxepin,CYP2C19,Ultrarapid Metabolizer,CYP2D6,None,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."
513,doxepin,CYP2C19,Rapid Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
514,doxepin,CYP2C19,Rapid Metabolizer,CYP2D6,Normal Metabolizer,"Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment."
515,doxepin,CYP2C19,Rapid Metabolizer,CYP2D6,Intermediate Metabolizer,"Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
516,doxepin,CYP2C19,Rapid Metabolizer,CYP2D6,Poor Metabolizer,"Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
517,doxepin,CYP2C19,Rapid Metabolizer,CYP2D6,Indeterminate,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."
518,doxepin,CYP2C19,Rapid Metabolizer,CYP2D6,None,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."
519,doxepin,CYP2C19,Normal Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment."
520,doxepin,CYP2C19,Normal Metabolizer,CYP2D6,Normal Metabolizer,Initiate therapy with recommended starting dose.
521,doxepin,CYP2C19,Normal Metabolizer,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
522,doxepin,CYP2C19,Normal Metabolizer,CYP2D6,Poor Metabolizer,"Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."
523,doxepin,CYP2C19,Normal Metabolizer,CYP2D6,Indeterminate,None
524,doxepin,CYP2C19,Normal Metabolizer,CYP2D6,None,None
525,doxepin,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
526,doxepin,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Normal Metabolizer,Initiate therapy with recommended starting dose.
527,doxepin,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
528,doxepin,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Poor Metabolizer,"Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
529,doxepin,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Indeterminate,None
530,doxepin,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,None,Initiate therapy with recommended starting dose.
531,doxepin,CYP2C19,Intermediate Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
532,doxepin,CYP2C19,Intermediate Metabolizer,CYP2D6,Normal Metabolizer,Initiate therapy with recommended starting dose.
533,doxepin,CYP2C19,Intermediate Metabolizer,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
534,doxepin,CYP2C19,Intermediate Metabolizer,CYP2D6,Poor Metabolizer,"Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
535,doxepin,CYP2C19,Intermediate Metabolizer,CYP2D6,Indeterminate,None
536,doxepin,CYP2C19,Intermediate Metabolizer,CYP2D6,None,Initiate therapy with recommended starting dose.
537,doxepin,CYP2C19,Likely Poor Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
538,doxepin,CYP2C19,Likely Poor Metabolizer,CYP2D6,Normal Metabolizer,"Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."
539,doxepin,CYP2C19,Likely Poor Metabolizer,CYP2D6,Intermediate Metabolizer,"Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
540,doxepin,CYP2C19,Likely Poor Metabolizer,CYP2D6,Poor Metabolizer,"Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
541,doxepin,CYP2C19,Likely Poor Metabolizer,CYP2D6,Indeterminate,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
542,doxepin,CYP2C19,Likely Poor Metabolizer,CYP2D6,None,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
543,doxepin,CYP2C19,Poor Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
544,doxepin,CYP2C19,Poor Metabolizer,CYP2D6,Normal Metabolizer,"Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."
545,doxepin,CYP2C19,Poor Metabolizer,CYP2D6,Intermediate Metabolizer,"Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
546,doxepin,CYP2C19,Poor Metabolizer,CYP2D6,Poor Metabolizer,"Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
547,doxepin,CYP2C19,Poor Metabolizer,CYP2D6,Indeterminate,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
548,doxepin,CYP2C19,Poor Metabolizer,CYP2D6,None,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
549,doxepin,CYP2C19,Indeterminate,CYP2D6,Ultrarapid Metabolizer,"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
550,doxepin,CYP2C19,Indeterminate,CYP2D6,Normal Metabolizer,None
551,doxepin,CYP2C19,Indeterminate,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
552,doxepin,CYP2C19,Indeterminate,CYP2D6,Poor Metabolizer,"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
553,doxepin,CYP2C19,Indeterminate,CYP2D6,Indeterminate,None
554,doxepin,CYP2C19,Indeterminate,CYP2D6,None,None
555,doxepin,CYP2C19,None,CYP2D6,Ultrarapid Metabolizer,"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
556,doxepin,CYP2C19,None,CYP2D6,Normal Metabolizer,Initiate therapy with recommended starting dose.
557,doxepin,CYP2C19,None,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
558,doxepin,CYP2C19,None,CYP2D6,Poor Metabolizer,"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
559,doxepin,CYP2C19,None,CYP2D6,Indeterminate,None
560,doxepin,CYP2C19,None,CYP2D6,None,None
561,imipramine,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
562,imipramine,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Normal Metabolizer,"Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment."
563,imipramine,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Intermediate Metabolizer,"Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
564,imipramine,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Poor Metabolizer,"Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
565,imipramine,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Indeterminate,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."
566,imipramine,CYP2C19,Ultrarapid Metabolizer,CYP2D6,None,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."
567,imipramine,CYP2C19,Rapid Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
568,imipramine,CYP2C19,Rapid Metabolizer,CYP2D6,Normal Metabolizer,"Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment."
569,imipramine,CYP2C19,Rapid Metabolizer,CYP2D6,Intermediate Metabolizer,"Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
570,imipramine,CYP2C19,Rapid Metabolizer,CYP2D6,Poor Metabolizer,"Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
571,imipramine,CYP2C19,Rapid Metabolizer,CYP2D6,Indeterminate,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."
572,imipramine,CYP2C19,Rapid Metabolizer,CYP2D6,None,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."
573,imipramine,CYP2C19,Normal Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment."
574,imipramine,CYP2C19,Normal Metabolizer,CYP2D6,Normal Metabolizer,Initiate therapy with recommended starting dose.
575,imipramine,CYP2C19,Normal Metabolizer,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
576,imipramine,CYP2C19,Normal Metabolizer,CYP2D6,Poor Metabolizer,"Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."
577,imipramine,CYP2C19,Normal Metabolizer,CYP2D6,Indeterminate,None
578,imipramine,CYP2C19,Normal Metabolizer,CYP2D6,None,Initiate therapy with recommended starting dose.
579,imipramine,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
580,imipramine,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Normal Metabolizer,Initiate therapy with recommended starting dose.
581,imipramine,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
582,imipramine,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Poor Metabolizer,"Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
583,imipramine,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Indeterminate,None
584,imipramine,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,None,Initiate therapy with recommended starting dose.
585,imipramine,CYP2C19,Intermediate Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
586,imipramine,CYP2C19,Intermediate Metabolizer,CYP2D6,Normal Metabolizer,Initiate therapy with recommended starting dose.
587,imipramine,CYP2C19,Intermediate Metabolizer,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
588,imipramine,CYP2C19,Intermediate Metabolizer,CYP2D6,Poor Metabolizer,"Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
589,imipramine,CYP2C19,Intermediate Metabolizer,CYP2D6,Indeterminate,None
590,imipramine,CYP2C19,Intermediate Metabolizer,CYP2D6,None,Initiate therapy with recommended starting dose.
591,imipramine,CYP2C19,Likely Poor Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
592,imipramine,CYP2C19,Likely Poor Metabolizer,CYP2D6,Normal Metabolizer,"Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."
593,imipramine,CYP2C19,Likely Poor Metabolizer,CYP2D6,Intermediate Metabolizer,"Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
594,imipramine,CYP2C19,Likely Poor Metabolizer,CYP2D6,Poor Metabolizer,"Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
595,imipramine,CYP2C19,Likely Poor Metabolizer,CYP2D6,Indeterminate,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
596,imipramine,CYP2C19,Likely Poor Metabolizer,CYP2D6,None,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
597,imipramine,CYP2C19,Poor Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
598,imipramine,CYP2C19,Poor Metabolizer,CYP2D6,Normal Metabolizer,"Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."
599,imipramine,CYP2C19,Poor Metabolizer,CYP2D6,Intermediate Metabolizer,"Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
600,imipramine,CYP2C19,Poor Metabolizer,CYP2D6,Poor Metabolizer,"Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
601,imipramine,CYP2C19,Poor Metabolizer,CYP2D6,Indeterminate,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
602,imipramine,CYP2C19,Poor Metabolizer,CYP2D6,None,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
603,imipramine,CYP2C19,Indeterminate,CYP2D6,Ultrarapid Metabolizer,"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
604,imipramine,CYP2C19,Indeterminate,CYP2D6,Normal Metabolizer,None
605,imipramine,CYP2C19,Indeterminate,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
606,imipramine,CYP2C19,Indeterminate,CYP2D6,Poor Metabolizer,"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
607,imipramine,CYP2C19,Indeterminate,CYP2D6,Indeterminate,None
608,imipramine,CYP2C19,Indeterminate,CYP2D6,None,None
609,imipramine,CYP2C19,None,CYP2D6,Ultrarapid Metabolizer,"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
610,imipramine,CYP2C19,None,CYP2D6,Normal Metabolizer,Initiate therapy with recommended starting dose.
611,imipramine,CYP2C19,None,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
612,imipramine,CYP2C19,None,CYP2D6,Poor Metabolizer,"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
613,imipramine,CYP2C19,None,CYP2D6,Indeterminate,None
614,imipramine,CYP2C19,None,CYP2D6,None,None
615,trimipramine,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
616,trimipramine,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Normal Metabolizer,"Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment."
617,trimipramine,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Intermediate Metabolizer,"Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
618,trimipramine,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Poor Metabolizer,"Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
619,trimipramine,CYP2C19,Ultrarapid Metabolizer,CYP2D6,Indeterminate,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."
620,trimipramine,CYP2C19,Ultrarapid Metabolizer,CYP2D6,None,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."
621,trimipramine,CYP2C19,Rapid Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
622,trimipramine,CYP2C19,Rapid Metabolizer,CYP2D6,Normal Metabolizer,"Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment."
623,trimipramine,CYP2C19,Rapid Metabolizer,CYP2D6,Intermediate Metabolizer,"Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
624,trimipramine,CYP2C19,Rapid Metabolizer,CYP2D6,Poor Metabolizer,"Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
625,trimipramine,CYP2C19,Rapid Metabolizer,CYP2D6,Indeterminate,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."
626,trimipramine,CYP2C19,Rapid Metabolizer,CYP2D6,None,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."
627,trimipramine,CYP2C19,Normal Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment."
628,trimipramine,CYP2C19,Normal Metabolizer,CYP2D6,Normal Metabolizer,Initiate therapy with recommended starting dose.
629,trimipramine,CYP2C19,Normal Metabolizer,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.
630,trimipramine,CYP2C19,Normal Metabolizer,CYP2D6,Poor Metabolizer,"Avoid trimipramine use. If a trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."
631,trimipramine,CYP2C19,Normal Metabolizer,CYP2D6,Indeterminate,None
632,trimipramine,CYP2C19,Normal Metabolizer,CYP2D6,None,Initiate therapy with recommended starting dose.
633,trimipramine,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
634,trimipramine,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Normal Metabolizer,Initiate therapy with recommended starting dose.
635,trimipramine,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
636,trimipramine,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Poor Metabolizer,"Avoid trimipramine use. If a trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
637,trimipramine,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,Indeterminate,None
638,trimipramine,CYP2C19,Likely Intermediate Metabolizer,CYP2D6,None,Initiate therapy with recommended starting dose.
639,trimipramine,CYP2C19,Intermediate Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
640,trimipramine,CYP2C19,Intermediate Metabolizer,CYP2D6,Normal Metabolizer,Initiate therapy with recommended starting dose.
641,trimipramine,CYP2C19,Intermediate Metabolizer,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.
642,trimipramine,CYP2C19,Intermediate Metabolizer,CYP2D6,Poor Metabolizer,"Avoid trimipramine use. If a trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
643,trimipramine,CYP2C19,Intermediate Metabolizer,CYP2D6,Indeterminate,None
644,trimipramine,CYP2C19,Intermediate Metabolizer,CYP2D6,None,Initiate therapy with recommended starting dose.
645,trimipramine,CYP2C19,Likely Poor Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
646,trimipramine,CYP2C19,Likely Poor Metabolizer,CYP2D6,Normal Metabolizer,"Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."
647,trimipramine,CYP2C19,Likely Poor Metabolizer,CYP2D6,Intermediate Metabolizer,"Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
648,trimipramine,CYP2C19,Likely Poor Metabolizer,CYP2D6,Poor Metabolizer,"Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
649,trimipramine,CYP2C19,Likely Poor Metabolizer,CYP2D6,Indeterminate,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
650,trimipramine,CYP2C19,Likely Poor Metabolizer,CYP2D6,None,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
651,trimipramine,CYP2C19,Poor Metabolizer,CYP2D6,Ultrarapid Metabolizer,"Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
652,trimipramine,CYP2C19,Poor Metabolizer,CYP2D6,Normal Metabolizer,"Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."
653,trimipramine,CYP2C19,Poor Metabolizer,CYP2D6,Intermediate Metabolizer,"Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
654,trimipramine,CYP2C19,Poor Metabolizer,CYP2D6,Poor Metabolizer,"Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended."
655,trimipramine,CYP2C19,Poor Metabolizer,CYP2D6,Indeterminate,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
656,trimipramine,CYP2C19,Poor Metabolizer,CYP2D6,None,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
657,trimipramine,CYP2C19,Indeterminate,CYP2D6,Ultrarapid Metabolizer,"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
658,trimipramine,CYP2C19,Indeterminate,CYP2D6,Normal Metabolizer,None
659,trimipramine,CYP2C19,Indeterminate,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
660,trimipramine,CYP2C19,Indeterminate,CYP2D6,Poor Metabolizer,"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
661,trimipramine,CYP2C19,Indeterminate,CYP2D6,Indeterminate,None
662,trimipramine,CYP2C19,Indeterminate,CYP2D6,None,None
663,trimipramine,CYP2C19,None,CYP2D6,Ultrarapid Metabolizer,"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
664,trimipramine,CYP2C19,None,CYP2D6,Normal Metabolizer,Initiate therapy with recommended starting dose.
665,trimipramine,CYP2C19,None,CYP2D6,Intermediate Metabolizer,Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
666,trimipramine,CYP2C19,None,CYP2D6,Poor Metabolizer,"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects."
667,trimipramine,CYP2C19,None,CYP2D6,Indeterminate,None
668,trimipramine,CYP2C19,None,CYP2D6,None,None
669,tropisetron,CYP2D6,Ultrarapid Metabolizer,None,None,"Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron)."
670,tropisetron,CYP2D6,Normal Metabolizer,None,None,Initiate therapy with recommended starting dose.
671,tropisetron,CYP2D6,Intermediate Metabolizer,None,None,Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.
672,tropisetron,CYP2D6,Poor Metabolizer,None,None,Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.
673,tropisetron,CYP2D6,Indeterminate,None,None,None
674,tramadol,CYP2D6,Ultrarapid Metabolizer,None,None,"Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid."
675,tramadol,CYP2D6,Normal Metabolizer,None,None,Use tramadol label recommended age- or weight-specific dosing.
676,tramadol,CYP2D6,Intermediate Metabolizer,None,None,"Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid."
677,tramadol,CYP2D6,Poor Metabolizer,None,None,"Avoid tramadol use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-codeine opioid."
678,tramadol,CYP2D6,Indeterminate,None,None,None
679,tamoxifen,CYP2D6,Ultrarapid Metabolizer,None,None,Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).
680,tamoxifen,CYP2D6,Normal Metabolizer,None,None,Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).
681,tamoxifen,CYP2D6,Intermediate Metabolizer,None,None,"Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors."
682,tamoxifen,CYP2D6,Poor Metabolizer,None,None,"Recommend alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827) and based on knowledge that CYP2D6 poor metabolizers switched from tamoxifen to anastrozole do not have an increased risk of recurrence (PMID 23213055). Note, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy (PMID 27226358, 21768473)."
683,tamoxifen,CYP2D6,Indeterminate,None,None,None
684,paroxetine,CYP2D6,Ultrarapid Metabolizer,None,None,Select alternative drug not predominantly metabolized by CYP2D6
685,paroxetine,CYP2D6,Normal Metabolizer,None,None,Initiate therapy with recommended starting dose
686,paroxetine,CYP2D6,Intermediate Metabolizer,None,None,Initiate therapy with recommended starting dose
687,paroxetine,CYP2D6,Poor Metabolizer,None,None,"Select alternative drug not predominantly metabolized by CYP2D6 or if paroxetine use warranted, consider a 50% reduction of recommended starting dose and titrate to response."
688,paroxetine,CYP2D6,Indeterminate,None,None,None
689,ondansetron,CYP2D6,Ultrarapid Metabolizer,None,None,"Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron)."
690,ondansetron,CYP2D6,Normal Metabolizer,None,None,Initiate therapy with recommended starting dose.
691,ondansetron,CYP2D6,Intermediate Metabolizer,None,None,Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.
692,ondansetron,CYP2D6,Poor Metabolizer,None,None,Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.
693,ondansetron,CYP2D6,Indeterminate,None,None,None
694,nortriptyline,CYP2D6,Ultrarapid Metabolizer,None,None,"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments."
695,nortriptyline,CYP2D6,Normal Metabolizer,None,None,Initiate therapy with recommended starting dose
696,nortriptyline,CYP2D6,Intermediate Metabolizer,None,None,Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
697,nortriptyline,CYP2D6,Poor Metabolizer,None,None,"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider a 50% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments."
698,nortriptyline,CYP2D6,Indeterminate,None,None,None
699,hydrocodone,CYP2D6,Ultrarapid Metabolizer,None,None,No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.
700,hydrocodone,CYP2D6,Normal Metabolizer,None,None,Use hydrocodone label recommended age- or weight-specific dosing.
701,hydrocodone,CYP2D6,Intermediate Metabolizer,None,None,"Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid."
702,hydrocodone,CYP2D6,Poor Metabolizer,None,None,"Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine and non-tramadol opioid."
703,hydrocodone,CYP2D6,Indeterminate,None,None,None
704,fluvoxamine,CYP2D6,Ultrarapid Metabolizer,None,None,None
705,fluvoxamine,CYP2D6,Normal Metabolizer,None,None,Initiate therapy with recommended starting dose.
706,fluvoxamine,CYP2D6,Intermediate Metabolizer,None,None,Initiate therapy with recommended starting dose.
707,fluvoxamine,CYP2D6,Poor Metabolizer,None,None,Consider a 25-50% reduction of recommended starting dose and titrate to response or use an alternative drug not metabolized by CYP2D6.
708,fluvoxamine,CYP2D6,Indeterminate,None,None,None
709,desipramine,CYP2D6,Ultrarapid Metabolizer,None,None,"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments."
710,desipramine,CYP2D6,Normal Metabolizer,None,None,Initiate therapy with recommended starting dose
711,desipramine,CYP2D6,Intermediate Metabolizer,None,None,Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.
712,desipramine,CYP2D6,Poor Metabolizer,None,None,"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments."
713,desipramine,CYP2D6,Indeterminate,None,None,None
714,codeine,CYP2D6,Ultrarapid Metabolizer,None,None,"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid."
715,codeine,CYP2D6,Normal Metabolizer,None,None,Use codeine label recommended age- or weight-specific dosing.
716,codeine,CYP2D6,Intermediate Metabolizer,None,None,"Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid."
717,codeine,CYP2D6,Poor Metabolizer,None,None,"Avoid codeine use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-tramadol opioid."
718,codeine,CYP2D6,Indeterminate,None,None,None
719,atomoxetine,CYP2D6,Ultrarapid Metabolizer,None,None,"Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations."
720,atomoxetine,CYP2D6,Normal Metabolizer,None,None,"Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations."
721,atomoxetine,CYP2D6,Intermediate Metabolizer,None,None,"Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations."
722,atomoxetine,CYP2D6,Poor Metabolizer,None,None,"Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks, consider obtaining a plasma concentration 2 to 4 hours after dosing. If concentration is <200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose."
723,atomoxetine,CYP2D6,Indeterminate,None,None,None
